Stock OCUL OCULAR THERAPEUTIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Ocular Therapeutix, Inc.

Equities

OCUL

US67576A1007

Delayed Nasdaq
Other stock markets
 15:53:24 2024-05-10 EDT 		5-day change 1st Jan Change
5.625 USD -3.68% Intraday chart for Ocular Therapeutix, Inc. -9.00% +25.90%
05-07 Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q1 Revenue $14.8M, vs. Street Est of $15.4M MT
05-07 Ocular Therapeutix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q1 Revenue $14.8M, vs. Street Est of $15.4M
MT
Ocular Therapeutix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup
DJ
Ocular Therapeutix Reports Positive Topline Data in Diabetic Retinopathy Trial; Shares Fall
MT
Ocular Therapeutix, Inc. Announces Positive Topline Phase 1 Data for AXPAXLI? in Diabetic Retinopathy
CI
Ocular Therapeutix, Inc. Announces Positive Phase 2 PAXTRAVA? Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
CI
Ocular Therapeutix Q4 Loss Widens, Revenue Rises -- Shares Down After Hours
MT
Ocular Therapeutix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q4 Revenue $14.8M, vs. Street Est of $15.7M
MT
Ocular Therapeutix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
North American Morning Briefing : Stock Futures -2-
DJ
AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority for DEXTENZA
CI
Ocular Therapeutix, Inc. Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of Axpaxli in Wet Amd
CI
Ocular Therapeutix Shares Rise as US FDA Modifies Enrollment Criteria, Drug Dosage for Axitinib Pivotal Study
MT
Ocular Therapeutix Announces FDA Agreement to Amend Special Protocol Assessment for Pivotal Clinical Trial of Axpaxli in Wet AMD
CI
Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q3 Revenue $15.1M
MT
Ocular Therapeutix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Ocular Therapeutix, Inc. Provides Earnings Guidance for the Full Year 2023
CI
Ocular Therapeutix to Start Patient Enrollment for Wet AMD Trial; Shares Gain
MT
Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OCUL Stock
  4. News Ocular Therapeutix, Inc.
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW